Intratect (Human Normal Immunoglobulin)

• Intratect is an intravenous immunoglobulin used to replace deficient antibodies in several immune‑related conditions.
• Primary immunodeficiency diseases: restores IgG levels to reduce infection risk.
• Secondary immunodeficiency: provides passive immunity when the immune system is compromised.
• Idiopathic thrombocytopenic purpura: helps raise platelet counts by modulating auto‑antibody activity.
• Kawasaki disease: reduces inflammation and coronary artery complications.
• Chronic inflammatory demyelinating polyneuropathy: improves nerve function by attenuating autoimmune attack.

• Human Normal Immunoglobulin supplies a broad spectrum of pooled IgG antibodies that bind and neutralize pathogens, opsonize microbes for phagocytosis, inhibit complement activation, and modulate Fc‑receptor–mediated immune cell functions, thereby providing passive immunity and regulating abnormal immune responses.

Intratect may cause a range of infusion‑related and systemic reactions.

Common Side Effects

• Headache: mild to moderate, often transient.
• Fever or chills: typically occurs during or shortly after infusion.
• Nausea or fatigue: may accompany the infusion process.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Aseptic meningitis: rare neurological complication presenting with headache and neck stiffness.
• Thromboembolic events or renal failure: can occur in high‑risk patients, especially with rapid infusion rates.

• Before initiating therapy, clinicians should assess patient‑specific risk factors and monitor for adverse events.
• Screen for IgA deficiency: evaluate anti‑IgA antibodies to reduce anaphylaxis risk.
• Monitor renal function: adjust infusion rate in patients with renal impairment.
• Assess thrombotic risk: use caution in individuals with cardiovascular disease.
• Observe for hemolysis: check hemoglobin levels during high‑dose regimens.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Intratect can interact with other therapies, influencing efficacy or safety.

Major Interactions (Avoid)

• Live vaccines: may diminish vaccine effectiveness; avoid concurrent administration.
• Rituximab: B‑cell depletion can reduce the therapeutic benefit of IVIG.

Moderate Interactions (Monitor Closely)

• Warfarin: IVIG may affect INR; monitor coagulation parameters.
• Diuretics: increased risk of renal dysfunction; observe fluid balance.
• ACE inhibitors: may potentiate hypertension; check blood pressure regularly.